Cargando…

2365. Effectiveness of COVID-19 Vaccines Against Medically Attended COVID-19 in Pregnant Persons Within the VISION Network, December 2021 - April 2023

BACKGROUND: Pregnant people have an increased risk of severe COVID-19, including hospitalization and critical illness. Currently, pregnant people are recommended to receive the same vaccinations as non-pregnant people of the same age and underlying health status (i.e., with or without immunocompromi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciesla, Allison Avrich, Link-Gelles, Ruth, Fleming-Dutra, Katherine E, Lazariu, Victoria, Dascomb, Kristin K, Grannis, Shaun J, Ong, Toan, Embi, Peter J, Ball, Sarah W, Gaglani, Manjusha, Kharbanda, Anupam, Natarajan, Karthik, Zerbo, Ousseny, Vazquez-Benitez, Gabriela, Irving, Stephanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678408/ http://dx.doi.org/10.1093/ofid/ofad500.1986

Ejemplares similares

Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023
por: Link-Gelles, Ruth, et al.
Publicado: (2023)

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023
por: Link-Gelles, Ruth, et al.
Publicado: (2023)

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022
por: Britton, Amadea, et al.
Publicado: (2022)

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
por: Klein, Nicola P., et al.
Publicado: (2022)

Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
por: Moulia, Danielle L., et al.
Publicado: (2023)

Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data Across 10 US States from August-December 2021
por: Embi, Peter J., et al.
Publicado: (2023)

LMOf2365_0442 Encoding for a Fructose Specific PTS Permease IIA May Be Required for Virulence in L. monocytogenes Strain F2365
por: Liu, Yanhong, et al.
Publicado: (2017)

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study
por: Adams, Katherine, et al.
Publicado: (2023)

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
por: Link-Gelles, Ruth, et al.
Publicado: (2023)

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
por: Tenforde, Mark W., et al.
Publicado: (2022)

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
por: Tenforde, Mark W., et al.
Publicado: (2023)

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
por: Link-Gelles, Ruth, et al.
Publicado: (2023)

461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023
por: Campbell, Angela P, et al.
Publicado: (2023)

Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023
por: Fleming-Dutra, Katherine E., et al.
Publicado: (2023)

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
por: Link-Gelles, Ruth, et al.
Publicado: (2022)

Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States
por: Schrag, Stephanie J., et al.
Publicado: (2022)

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022
por: Natarajan, Karthik, et al.
Publicado: (2022)

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
por: Ferdinands, Jill M, et al.
Publicado: (2022)

2365: PTSD: Understanding differences in trauma cognitions, memory, and emotional regulation
por: Volpe, Ellen, et al.
Publicado: (2018)

2365. Volatile Metabolite-Based Detection of Clostridium difficile Infection (CDI)
por: Aloum, Obadah, et al.
Publicado: (2019)

April 2023 obituaries
Publicado: (2023)

Update on the status of COVID-19 vaccination in Italy—April 2023
por: Mattiuzzi, Camilla, et al.
Publicado: (2023)

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
por: Thompson, Mark G., et al.
Publicado: (2022)

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
por: Ferdinands, Jill M., et al.
Publicado: (2022)

Inside the April 2023 Issue
por: Galen, Benjamin T
Publicado: (2023)

Editors’ roundup: April 2023
por: Tame, Jeremy, et al.
Publicado: (2023)

2365. Post-operative Vertebral Osteomyelitis—A Disease With Distinct Clinical and Microbiological Characteristics
por: Breuninger, Marianne, et al.
Publicado: (2018)

The Long-Term Impacts of COVID-19 on Physical and Psychological Health — Beijing Municipality, China, December 2022–April 2023
por: Tian, Tian, et al.
Publicado: (2023)

Reassessing the role of internalin B in Listeria monocytogenes virulence using the epidemic strain F2365
por: Quereda, J.J., et al.
Publicado: (2019)

2365. Fostering the Future: Improving Infection Prevention and Control Education in Pediatric Infectious Diseases Fellowship
por: Fatemi, Yasaman, et al.
Publicado: (2022)

CBI4AI at CERN - April 2023
por: Poulaillon, Jimmy, et al.
Publicado: (2023)

Avian influenza overview March – April 2023
por: Adlhoch, Cornelia, et al.
Publicado: (2023)

Human Vaccines & Immunotherapeutics: News April 2023
por: Ellis, Ronald, et al.
Publicado: (2023)

Avian influenza overview April – June 2023
por: Adlhoch, Cornelia, et al.
Publicado: (2023)

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
por: Thompson, Mark G., et al.
Publicado: (2021)

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
por: Link-Gelles, Ruth, et al.
Publicado: (2022)

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021
por: Embi, Peter J., et al.
Publicado: (2021)

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021
por: Embi, Peter J., et al.
Publicado: (2022)

In this issue: Volume 114, Issue 4, April 2023
Publicado: (2023)

Erratum, Vol. 20, April 13, 2023 Release
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ktn53ospqmre1o6bdapm6r8eou